Advances in translational research of the rare cancer type adrenocortical carcinoma.
Journal
Nature reviews. Cancer
ISSN: 1474-1768
Titre abrégé: Nat Rev Cancer
Pays: England
ID NLM: 101124168
Informations de publication
Date de publication:
Dec 2023
Dec 2023
Historique:
accepted:
30
08
2023
medline:
24
11
2023
pubmed:
20
10
2023
entrez:
19
10
2023
Statut:
ppublish
Résumé
Adrenocortical carcinoma is a rare malignancy with an annual worldwide incidence of 1-2 cases per 1 million and a 5-year survival rate of <60%. Although adrenocortical carcinoma is rare, such rare cancers account for approximately one third of patients diagnosed with cancer annually. In the past decade, there have been considerable advances in understanding the molecular basis of adrenocortical carcinoma. The genetic events associated with adrenocortical carcinoma in adults are distinct from those of paediatric cases, which are often associated with germline or somatic TP53 mutations and have a better prognosis. In adult primary adrenocortical carcinoma, the main somatic genetic alterations occur in genes that encode proteins involved in the WNT-β-catenin pathway, cell cycle and p53 apoptosis pathway, chromatin remodelling and telomere maintenance pathway, cAMP-protein kinase A (PKA) pathway or DNA transcription and RNA translation pathways. Recently, integrated molecular studies of adrenocortical carcinomas, which have characterized somatic mutations and the methylome as well as gene and microRNA expression profiles, have led to a molecular classification of these tumours that can predict prognosis and have helped to identify new therapeutic targets. In this Review, we summarize these recent translational research advances in adrenocortical carcinoma, which it is hoped could lead to improved patient diagnosis, treatment and outcome.
Identifiants
pubmed: 37857840
doi: 10.1038/s41568-023-00623-0
pii: 10.1038/s41568-023-00623-0
doi:
Substances chimiques
Transcription Factors
0
Types de publication
Journal Article
Review
Langues
eng
Sous-ensembles de citation
IM
Pagination
805-824Informations de copyright
© 2023. Springer Nature Limited.
Références
Bilimoria, K. Y. et al. Adrenocortical carcinoma in the United States: treatment utilization and prognostic factors. Cancer 113, 3130–3136 (2008).
pubmed: 18973179
Else, T. et al. Adrenocortical carcinoma. Endocr. Rev. 35, 282–326 (2014).
pubmed: 24423978
Kebebew, E., Reiff, E., Duh, Q. Y., Clark, O. H. & McMillan, A. Extent of disease at presentation and outcome for adrenocortical carcinoma: have we made progress? World J. Surg. 30, 872–878 (2006).
pubmed: 16680602
Tella, S. H., Kommalapati, A., Yaturu, S. & Kebebew, E. Predictors of survival in adrenocortical carcinoma: an analysis from the national cancer database. J. Clin. Endocrinol. Metab. 103, 3566–3573 (2018).
pubmed: 29982685
Tierney, J. F. et al. National treatment practice for adrenocortical carcinoma: have they changed and have we made any progress? J. Clin. Endocrinol. Metab. 104, 5948–5956 (2019).
pubmed: 31361313
Kerkhofs, T. M. et al. Adrenocortical carcinoma: a population-based study on incidence and survival in the Netherlands since 1993. Eur. J. Cancer 49, 2579–2586 (2013).
pubmed: 23561851
McAteer, J. P., Huaco, J. A. & Gow, K. W. Predictors of survival in pediatric adrenocortical carcinoma: a Surveillance, Epidemiology, and End Results (SEER) program study. J. Pediatr. Surg. 48, 1025–1031 (2013).
pubmed: 23701777
Fassnacht, M. et al. Limited prognostic value of the 2004 International Union Against Cancer staging classification for adrenocortical carcinoma: proposal for a revised TNM classification. Cancer 115, 243–250 (2009).
pubmed: 19025987
Elhassan, Y. S. et al. S-GRAS score for prognostic classification of adrenocortical carcinoma: an international, multicenter ENSAT study. Eur. J. Endocrinol. 186, 25–36 (2021).
pubmed: 34709200
pmcid: 8679848
Beuschlein, F. et al. Major prognostic role of Ki67 in localized adrenocortical carcinoma after complete resection. J. Clin. Endocrinol. Metab. 100, 841–849 (2015).
pubmed: 25559399
Michalkiewicz, E. et al. Clinical and outcome characteristics of children with adrenocortical tumors: a report from the International Pediatric Adrenocortical Tumor Registry. J. Clin. Oncol. 22, 838–845 (2004).
pubmed: 14990639
Loncar, Z. et al. Survival and prognostic factors for adrenocortical carcinoma: a single institution experience. BMC Urol. 15, 43 (2015).
pubmed: 26013141
pmcid: 4443614
Li, P., Su, X., Zhang, X., Sun, L. & Zhang, G. Prognostic factors of adrenocortical carcinoma: experience from a Regional Medical Center in Eastern China. Int. J. Gen. Med. 16, 453–465 (2023).
pubmed: 36760685
pmcid: 9904150
Lughezzani, G. et al. The European Network for the Study of Adrenal Tumors staging system is prognostically superior to the International Union Against Cancer-staging system: a North American validation. Eur. J. Cancer 46, 713–719 (2010).
pubmed: 20044246
Terzolo, M. et al. Results of the ADIUVO study, the first randomized trial on adjuvant mitotane in adrenocortical carcinoma patients. J. Endocr. Soc. 5, A166–A167 (2021).
pmcid: 8265733
Fassnacht, M. et al. Combination chemotherapy in advanced adrenocortical carcinoma. N. Engl. J. Med. 366, 2189–2197 (2012).
pubmed: 22551107
Fassnacht, M. et al. European Society of Endocrinology Clinical Practice Guidelines on the management of adrenocortical carcinoma in adults, in collaboration with the European Network for the Study of Adrenal Tumors. Eur. J. Endocrinol. 179, G1–G46 (2018).
pubmed: 30299884
Challis, B. G. et al. Familial adrenocortical carcinoma in association with Lynch syndrome. J. Clin. Endocrinol. Metab. 101, 2269–2272 (2016).
pubmed: 27144940
pmcid: 4891804
Gatta-Cherifi, B. et al. Adrenal involvement in MEN1. Analysis of 715 cases from the Groupe d’Etude des Tumeurs Endocrines database. Eur. J. Endocrinol. 166, 269–279 (2012).
pubmed: 22084155
Hampel, H. et al. Screening for the Lynch syndrome (hereditary nonpolyposis colorectal cancer). N. Engl. J. Med. 352, 1851–1860 (2005).
pubmed: 15872200
Herrmann, L. J. et al. TP53 germline mutations in adult patients with adrenocortical carcinoma. J. Clin. Endocrinol. Metab. 97, E476–E485 (2012).
pubmed: 22170717
MacFarland, S. P. et al. Management of adrenal masses in patients with Beckwith–Wiedemann syndrome. Pediatr. Blood Cancer 64, 10.1002/pbc.26432 (2017).
pmcid: 5944603
Pinto, E. M. et al. Identification of clinical and biologic correlates associated with outcome in children with adrenocortical tumors without germline TP53 mutations: a st jude adrenocortical tumor registry and children’s oncology group study. J. Clin. Oncol. 35, 3956–3963 (2017).
pubmed: 29058986
pmcid: 5721229
Raymond, V. M. et al. Prevalence of germline TP53 mutations in a prospective series of unselected patients with adrenocortical carcinoma. J. Clin. Endocrinol. Metab. 98, E119–E125 (2013).
pubmed: 23175693
Raymond, V. M. et al. Adrenocortical carcinoma is a Lynch syndrome-associated cancer. J. Clin. Oncol. 31, 3012–3018 (2013).
pubmed: 23752102
pmcid: 3739861
Seki, M. et al. Loss of normal allele of the APC gene in an adrenocortical carcinoma from a patient with familial adenomatous polyposis. Hum. Genet. 89, 298–300 (1992).
pubmed: 1351034
Shiroky, J. S., Lerner-Ellis, J. P., Govindarajan, A., Urbach, D. R. & Devon, K. M. Characteristics of adrenal masses in familial adenomatous polyposis. Dis. Colon Rectum 61, 679–685 (2018).
pubmed: 29377868
Wakatsuki, S. et al. Adrenocortical tumor in a patient with familial adenomatous polyposis: a case associated with a complete inactivating mutation of the APC gene and unusual histological features. Hum. Pathol. 29, 302–306 (1998).
pubmed: 9496836
Wasserman, J. D. et al. Prevalence and functional consequence of TP53 mutations in pediatric adrenocortical carcinoma: a Children’s Oncology Group study. J. Clin. Oncol. 33, 602–609 (2015).
pubmed: 25584008
pmcid: 4517369
Juhlin, C. C. et al. What did we learn from the molecular biology of adrenal cortical neoplasia? From histopathology to translational genomics. Endocr. Pathol. 32, 102–133 (2021).
pubmed: 33534120
Grisanti, S., Cosentini, D., Sigala, S. & Berruti, A. Molecular genotyping of adrenocortical carcinoma: a systematic analysis of published literature 2019–2021. Curr. Opin. Oncol. 34, 19–28 (2022).
pubmed: 34669649
Else, T. et al. Adrenocortical carcinoma and succinate dehydrogenase gene mutations: an observational case series. Eur. J. Endocrinol. 177, 439–444 (2017).
pubmed: 28819017
Grisanti, S. et al. 29MO Germline variants NGS characterization in patients with non-syndromic adrenocortical carcinoma. ESMO Open 8, 101050 (2023).
Custodio, G. et al. Impact of neonatal screening and surveillance for the TP53 R337H mutation on early detection of childhood adrenocortical tumors. J. Clin. Oncol. 31, 2619–2626 (2013).
pubmed: 23733769
pmcid: 3808236
Latronico, A. C. et al. An inherited mutation outside the highly conserved DNA-binding domain of the p53 tumor suppressor protein in children and adults with sporadic adrenocortical tumors. J. Clin. Endocrinol. Metab. 86, 4970–4973 (2001).
pubmed: 11600572
Pinto, E. M. et al. Founder effect for the highly prevalent R337H mutation of tumor suppressor p53 in Brazilian patients with adrenocortical tumors. Arq. Bras. Endocrinol. Metab. 48, 647–650 (2004).
Ribeiro, R. C. et al. An inherited p53 mutation that contributes in a tissue-specific manner to pediatric adrenal cortical carcinoma. Proc. Natl Acad. Sci. USA 98, 9330–9335 (2001).
pubmed: 11481490
pmcid: 55420
Mete, O. et al. Overview of the 2022 who classification of adrenal cortical tumors. Endocr. Pathol. 33, 155–196 (2022).
pubmed: 35288842
pmcid: 8920443
Minner, S., Schreiner, J. & Saeger, W. Adrenal cancer: relevance of different grading systems and subtypes. Clin. Transl. Oncol. 23, 1350–1357 (2021).
pubmed: 33818702
pmcid: 8192347
Weiss, L. M. Comparative histologic study of 43 metastasizing and nonmetastasizing adrenocortical tumors. Am. J. Surg. Pathol. 8, 163–169 (1984).
pubmed: 6703192
Weiss, L. M., Medeiros, L. J. & Vickery, A. L. Jr Pathologic features of prognostic significance in adrenocortical carcinoma. Am. J. Surg. Pathol. 13, 202–206 (1989).
pubmed: 2919718
Pittaway, J. F. H. & Guasti, L. Pathobiology and genetics of adrenocortical carcinoma. J. Mol. Endocrinol. 62, R105–R119 (2019).
pubmed: 30072419
Assie, G. et al. Integrated genomic characterization of adrenocortical carcinoma. Nat. Genet. 46, 607–612 (2014). This study demonstrates that cataloguing the genomic changes in adrenocortical carcinoma reveals distinct molecular groups and that these are associated with prognosis.
pubmed: 24747642
Zheng, S. et al. Comprehensive pan-genomic characterization of adrenocortical carcinoma. Cancer Cell 29, 723–736 (2016). This study comprehensively identifies genomic alterations associated with adult adrenocortical carcinoma and their association with patient outcome.
pubmed: 27165744
pmcid: 4864952
Sbiera, I. et al. Role of FGF receptors and their pathways in adrenocortical tumors and possible therapeutic implications. Front. Endocrinol. 12, 795116 (2021).
Tamburello, M. et al. FGF/FGFR signaling in adrenocortical development and tumorigenesis: novel potential therapeutic targets in adrenocortical carcinoma. Endocrine 77, 411–418 (2022).
pubmed: 35583844
pmcid: 9385797
Pereira, S. S. et al. IGF2 role in adrenocortical carcinoma biology. Endocrine 66, 326–337 (2019).
pubmed: 31378849
pmcid: 6838304
Pinto, E. M. et al. Genomic landscape of paediatric adrenocortical tumours. Nat. Commun. 6, 6302 (2015). This study shows the genomic alterations that are prevalent in and unique to paediatric adrenocortical carcinomas.
pubmed: 25743702
Pozdeyev, N. et al. Targeted genomic analysis of 364 adrenocortical carcinomas. Endocr. Relat. Cancer 28, 671–681 (2021). This study is one of the largest mutational analyses performed using NGS and identifies novel genomic alterations that could be targeted for therapy.
pubmed: 34410225
pmcid: 8384129
Hoadley, K. A. et al. Cell-of-origin patterns dominate the molecular classification of 10,000 tumors from 33 types of cancer. Cell 173, 291–304.e6 (2018).
pubmed: 29625048
pmcid: 5957518
Knijnenburg, T. A. et al. Genomic and molecular landscape of DNA damage repair deficiency across the cancer genome atlas. Cell Rep. 23, 239–254.e6 (2018).
pubmed: 29617664
pmcid: 5961503
Sondka, Z. et al. The COSMIC cancer gene census: describing genetic dysfunction across all human cancers. Nat. Rev. Cancer 18, 696–705 (2018).
pubmed: 30293088
pmcid: 6450507
Kurtz, A. et al. Somatic mitochondrial DNA mutations in neurofibromatosis type 1-associated tumors. Mol. Cancer Res. 2, 433–441 (2004).
pubmed: 15328370
Wang, Q. et al. Neurofibromatosis type 1 gene as a mutational target in a mismatch repair-deficient cell type. Hum. Genet. 112, 117–123 (2003).
pubmed: 12522551
Santos, M. A. et al. DNA-damage-induced differentiation of leukaemic cells as an anti-cancer barrier. Nature 514, 107–111 (2014).
pubmed: 25079327
pmcid: 4410707
Pemov, A., Park, C., Reilly, K. M. & Stewart, D. R. Evidence of perturbations of cell cycle and DNA repair pathways as a consequence of human and murine NF1-haploinsufficiency. BMC Genomics 11, 194 (2010).
pubmed: 20307317
pmcid: 2858150
Bielski, C. M. et al. Genome doubling shapes the evolution and prognosis of advanced cancers. Nat. Genet. 50, 1189–1195 (2018).
pubmed: 30013179
pmcid: 6072608
Letouze, E. et al. SNP array profiling of childhood adrenocortical tumors reveals distinct pathways of tumorigenesis and highlights candidate driver genes. J. Clin. Endocrinol. Metab. 97, E1284–E1293 (2012).
pubmed: 22539591
Zack, T. I. et al. Pan-cancer patterns of somatic copy number alteration. Nat. Genet. 45, 1134–1140 (2013).
pubmed: 24071852
pmcid: 3966983
Juhlin, C. C. et al. Whole-exome sequencing characterizes the landscape of somatic mutations and copy number alterations in adrenocortical carcinoma. J. Clin. Endocrinol. Metab. 100, E493–E502 (2015).
pubmed: 25490274
Gicquel, C. et al. Rearrangements at the 11p15 locus and overexpression of insulin-like growth factor-II gene in sporadic adrenocortical tumors. J. Clin. Endocrinol. Metab. 78, 1444–1453 (1994).
pubmed: 7911125
Gicquel, C. et al. Structural and functional abnormalities at 11p15 are associated with the malignant phenotype in sporadic adrenocortical tumors: study on a series of 82 tumors. J. Clin. Endocrinol. Metab. 82, 2559–2565 (1997).
pubmed: 9253334
Peixoto Lira, R. C. et al. IGF2 and IGF1R in pediatric adrenocortical tumors: roles in metastasis and steroidogenesis. Endocr. Relat. Cancer 23, 481–493 (2016).
pubmed: 27185872
Guillaud-Bataille, M. et al. IGF2 promotes growth of adrenocortical carcinoma cells, but its overexpression does not modify phenotypic and molecular features of adrenocortical carcinoma. PLoS ONE 9, e103744 (2014).
pubmed: 25089899
pmcid: 4121173
Nielsen, H. M. et al. Copy number variations alter methylation and parallel IGF2 overexpression in adrenal tumors. Endocr. Relat. Cancer 22, 953–967 (2015).
pubmed: 26400872
pmcid: 4621769
Rosati, R. et al. High frequency of loss of heterozygosity at 11p15 and IGF2 overexpression are not related to clinical outcome in childhood adrenocortical tumors positive for the R337H TP53 mutation. Cancer Genet. Cytogenet. 186, 19–24 (2008).
pubmed: 18786438
pmcid: 2603647
Szabo, P. E., Tang, S. H., Silva, F. J., Tsark, W. M. & Mann, J. R. Role of CTCF binding sites in the Igf2/H19 imprinting control region. Mol. Cell Biol. 24, 4791–4800 (2004).
pubmed: 15143173
pmcid: 416431
Barlaskar, F. M. et al. Preclinical targeting of the type I insulin-like growth factor receptor in adrenocortical carcinoma. J. Clin. Endocrinol. Metab. 94, 204–212 (2009).
pubmed: 18854392
US National Library of Medicine. ClinicalTrials.gov https://www.clinicaltrials.gov/study/NCT00831844 (2015).
Fassnacht, M. et al. Linsitinib (OSI-906) versus placebo for patients with locally advanced or metastatic adrenocortical carcinoma: a double-blind, randomised, phase 3 study. Lancet Oncol. 16, 426–35 (2015).
pubmed: 25795408
Sasano, H., Satoh, F. & Nakamura, Y. Roles of the pathologist in evaluating surrogate markers for medical therapy in adrenocortical carcinoma. Endocr. Pathol. 25, 366–370 (2014).
pubmed: 25252621
Adam, P. et al. Epidermal growth factor receptor in adrenocortical tumors: analysis of gene sequence, protein expression and correlation with clinical outcome. Mod. Pathol. 23, 1596–1604 (2010).
pubmed: 20693985
Quinkler, M. et al. Treatment of advanced adrenocortical carcinoma with erlotinib plus gemcitabine. J. Clin. Endocrinol. Metab. 93, 2057–2062 (2008).
pubmed: 18334586
Ardolino, L., Hansen, A., Ackland, S. & Joshua, A. Advanced adrenocortical carcinoma (ACC): a review with focus on second-line therapies. Horm. Cancer 11, 155–169 (2020).
pubmed: 32303972
pmcid: 10355245
Boumahdi, S. & de Sauvage, F. J. The great escape: tumour cell plasticity in resistance to targeted therapy. Nat. Rev. Drug Discov. 19, 39–56 (2020).
pubmed: 31601994
Quintanal-Villalonga, Á. et al. Lineage plasticity in cancer: a shared pathway of therapeutic resistance. Nat. Rev. Clin. Oncol. 17, 360–371 (2020).
pubmed: 32152485
pmcid: 7397755
Gara, S. K. et al. Metastatic adrenocortical carcinoma displays higher mutation rate and tumor heterogeneity than primary tumors. Nat. Commun. 9, 4172 (2018). This study demonstrates that genomic alterations between primary adrenocortical carcinoma and recurrent and metastatic adrenocortical carcinoma are different with the latter exhibiting more tumour heterogeneity.
pubmed: 30301885
pmcid: 6178360
Heaton, J. H. et al. Progression to adrenocortical tumorigenesis in mice and humans through insulin-like growth factor 2 and β-catenin. Am. J. Pathol. 181, 1017–1033 (2012).
pubmed: 22800756
pmcid: 3432433
Berthon, A. et al. Constitutive beta-catenin activation induces adrenal hyperplasia and promotes adrenal cancer development. Hum. Mol. Genet. 19, 1561–1576 (2010).
pubmed: 20106872
Lin, S. & Gregory, R. I. MicroRNA biogenesis pathways in cancer. Nat. Rev. Cancer 15, 321–333 (2015).
pubmed: 25998712
pmcid: 4859809
Huarte, M. The emerging role of lncRNAs in cancer. Nat. Med. 21, 1253–1261 (2015).
pubmed: 26540387
Liu, J., Kahri, A. I., Heikkila, P., Ilvesmaki, V. & Voutilainen, R. H19 and insulin-like growth factor-II gene expression in adrenal tumors and cultured adrenal cells. J. Clin. Endocrinol. Metab. 80, 492–496 (1995).
pubmed: 7531713
Hatada, I. & Mukai, T. Genomic imprinting of p57KIP2, a cyclin-dependent kinase inhibitor, in mouse. Nat. Genet. 11, 204–206 (1995).
pubmed: 7550351
Liu, J., Kahri, A. I., Heikkila, P. & Voutilainen, R. Ribonucleic acid expression of the clustered imprinted genes, p57
pubmed: 9177379
Soon, P. S. et al. miR-195 and miR-483-5p identified as predictors of poor prognosis in adrenocortical cancer. Clin. Cancer Res. 15, 7684–7692 (2009).
pubmed: 19996210
Feinmesser, M. et al. Specific microRNAs differentiate adrenocortical adenomas from carcinomas and correlate with Weiss histopathologic system. Appl. Immunohistochem. Mol. Morphol. 23, 522–531 (2015).
pubmed: 25265426
Koperski, Ł. et al. Next-generation sequencing reveals microRNA markers of adrenocortical tumors malignancy. Oncotarget 8, 49191–49200 (2017).
pubmed: 28423361
pmcid: 5564760
Chehade, M., Bullock, M., Glover, A., Hutvagner, G. & Sidhu, S. Key microRNA’s and their targetome in adrenocortical cancer. Cancers 12, 2198 (2020).
pubmed: 32781574
pmcid: 7465134
Mitchell, P. S. et al. Circulating microRNAs as stable blood-based markers for cancer detection. Proc. Natl Acad. Sci. USA 105, 10513–10518 (2008).
pubmed: 18663219
pmcid: 2492472
Chabre, O. et al. Serum miR-483-5p and miR-195 are predictive of recurrence risk in adrenocortical cancer patients. Endocr. Relat. Cancer 20, 579–594 (2013).
pubmed: 23756429
Szabó, D. R. et al. Analysis of circulating microRNAs in adrenocortical tumors. Lab. Invest. 94, 331–339 (2014).
pubmed: 24336071
Patel, D. et al. MiR-34a and miR-483-5p are candidate serum biomarkers for adrenocortical tumors. Surgery 154, 1224–1228 (2013).
pubmed: 24238045
Wu, Y. et al. MicroRNA-205 suppresses the growth of adrenocortical carcinoma SW-13 cells via targeting Bcl-2. Oncol. Rep. 34, 3104–3110 (2015).
pubmed: 26397843
Jain, M. et al. ZNF367 inhibits cancer progression and is targeted by miR-195. PLoS ONE 9, e101423 (2014).
pubmed: 25047265
pmcid: 4105551
Kwok, G. T. Y. et al. microRNA-431 as a chemosensitizer and potentiator of drug activity in adrenocortical carcinoma. Oncologist 24, e241–e250 (2019).
pubmed: 30918109
pmcid: 6656493
Hassan, N., Zhao, J. T., Glover, A., Robinson, B. G. & Sidhu, S. B. Reciprocal interplay of miR-497 and MALAT1 promotes tumourigenesis of adrenocortical cancer. Endocr. Relat. Cancer 26, 677–688 (2019).
pubmed: 31085769
Kalinowski, F. C. et al. microRNA-7: a tumor suppressor miRNA with therapeutic potential. Int. J. Biochem. Cell Biol. 54, 312–317 (2014).
pubmed: 24907395
Gara, S. K. et al. Integrated genome-wide analysis of genomic changes and gene regulation in human adrenocortical tissue samples. Nucleic Acids Res. 43, 9327–9339 (2015).
pubmed: 26446994
pmcid: 4627080
Glover, A. R. et al. Long noncoding RNA profiles of adrenocortical cancer can be used to predict recurrence. Endocr. Relat. Cancer 22, 99–109 (2015). One of the first studies to show that the lncRNA expression profile of adrenocortical carcinoma is different from that of benign adrenocortical carcinoma and normal adrenal cortex.
pubmed: 25595289
Buishand, F. O. et al. Adrenocortical tumors have a distinct, long, non-coding RNA expression profile and LINC00271 is downregulated in malignancy. Surgery 167, 224–232 (2020).
pubmed: 31522749
Long, B. et al. Long noncoding RNA ASB16-AS1 inhibits adrenocortical carcinoma cell growth by promoting ubiquitination of RNA-binding protein HuR. Cell Death Dis. 11, 995 (2020).
pubmed: 33219221
pmcid: 7679391
Guo, N., Sun, Q., Fu, D. & Zhang, Y. Long non-coding RNA UCA1 promoted the growth of adrenocortical cancer cells via modulating the miR-298-CDK6 axis. Gene 703, 26–34 (2019).
pubmed: 30935924
Tombol, Z. et al. Integrative molecular bioinformatics study of human adrenocortical tumors: microRNA, tissue-specific target prediction, and pathway analysis. Endocr. Relat. Cancer 16, 895–906 (2009).
pubmed: 19546168
Duregon, E. et al. MicroRNA expression patterns in adrenocortical carcinoma variants and clinical pathologic correlations. Hum. Pathol. 45, 1555–1562 (2014).
pubmed: 24890943
Ozata, D. M. et al. The role of microRNA deregulation in the pathogenesis of adrenocortical carcinoma. Endocr. Relat. Cancer 18, 643–655 (2011).
pubmed: 21859927
pmcid: 3201061
Patterson, E. E., Holloway, A. K., Weng, J., Fojo, T. & Kebebew, E. MicroRNA profiling of adrenocortical tumors reveals miR-483 as a marker of malignancy. Cancer 117, 1630–1639 (2011).
pubmed: 21472710
Ettaieb, M., Kerkhofs, T., van Engeland, M. & Haak, H. Past, present and future of epigenetics in adrenocortical carcinoma. Cancers 12, 1218 (2020).
pubmed: 32414074
pmcid: 7281315
Rechache, N. S. et al. DNA methylation profiling identifies global methylation differences and markers of adrenocortical tumors. J. Clin. Endocrinol. Metab. 97, E1004–E1013 (2012).
pubmed: 22472567
pmcid: 3387424
Creemers, S. G. et al. Methylation of IGF2 regulatory regions to diagnose adrenocortical carcinomas. Endocr. Relat. Cancer 23, 727–737 (2016).
pubmed: 27535174
Barreau, O. et al. Identification of a CpG island methylator phenotype in adrenocortical carcinomas. J. Clin. Endocrinol. Metab. 98, E174–E184 (2013).
pubmed: 23093492
Jouinot, A. et al. DNA methylation is an independent prognostic marker of survival in adrenocortical cancer. J. Clin. Endocrinol. Metab. 102, 923–932 (2017).
pubmed: 27967600
Lippert, J. et al. Prognostic role of targeted methylation analysis in paraffin-embedded samples of adrenocortical carcinoma. J. Clin. Endocrinol. Metab. 107, 2892–2899 (2022).
pubmed: 35929659
pmcid: 9516165
Mohan, D. R. et al. Targeted assessment of G0S2 methylation identifies a rapidly recurrent, routinely fatal molecular subtype of adrenocortical carcinoma. Clin. Cancer Res. 25, 3276–3288 (2019).
pubmed: 30770352
pmcid: 7117545
Clay, M. R. et al. DNA methylation profiling reveals prognostically significant groups in pediatric adrenocortical tumors: a report from the International Pediatric Adrenocortical Tumor Registry. JCO Precis. Oncol. 3, PO.19.00163 (2019).
pubmed: 32923859
pmcid: 7446418
Drelon, C. et al. EZH2 is overexpressed in adrenocortical carcinoma and is associated with disease progression. Hum. Mol. Genet. 25, 2789–2800 (2016).
pubmed: 27149985
pmcid: 6095221
Tabbal, H. et al. EZH2 cooperates with E2F1 to stimulate expression of genes involved in adrenocortical carcinoma aggressiveness. Br. J. Cancer 121, 384–394 (2019).
pubmed: 31363169
pmcid: 6738105
Kebebew, E. Adrenal incidentaloma. N. Engl. J. Med. 384, 1542–1551 (2021).
pubmed: 33882207
Rege, J., Turcu, A. F., Else, T., Auchus, R. J. & Rainey, W. E. Steroid biomarkers in human adrenal disease. J. Steroid Biochem. Mol. Biol. 190, 273–280 (2019).
pubmed: 30707926
pmcid: 6707065
Taylor, D. R. et al. A 13-steroid serum panel based on LC-MS/MS: use in detection of adrenocortical carcinoma. Clin. Chem. 63, 1836–1846 (2017). Along with Rege et al. (2019), this study shows the utility of measuring levels of steroids and their metabolities as biomarkers of adrenocortical carcinoma.
pubmed: 28904054
Chortis, V. et al. Urine steroid metabolomics as a novel tool for detection of recurrent adrenocortical carcinoma. J. Clin. Endocrinol. Metab. 105, e307–e318 (2020).
pubmed: 31665449
Suzuki, S. et al. Steroid metabolites for diagnosing and predicting clinicopathological features in cortisol-producing adrenocortical carcinoma. BMC Endocr. Disord. 20, 173 (2020).
pubmed: 33228607
pmcid: 7686776
Bancos, I. et al. Urine steroid metabolomics for the differential diagnosis of adrenal incidentalomas in the EURINE-ACT study: a prospective test validation study. Lancet Diabetes Endocrinol. 8, 773–781 (2020).
pubmed: 32711725
pmcid: 7447976
Patel, D. et al. Unique and novel urinary metabolomic features in malignant versus benign adrenal neoplasms. Clin. Cancer Res. 23, 5302–5310 (2017). This study shows that patients with adrenocortical carcinoma have a unique urinary metabolome, which derives from the tumour tissue.
pubmed: 28450405
pmcid: 5581680
Mathe, E. A. et al. Noninvasive urinary metabolomic profiling identifies diagnostic and prognostic markers in lung cancer. Cancer Res. 74, 3259–3270 (2014).
pubmed: 24736543
pmcid: 4100625
Haznadar, M. et al. Urinary metabolites diagnostic and prognostic of intrahepatic cholangiocarcinoma. Cancer Epidemiol. Biomark. Prev. 28, 1704–1711 (2019).
Foster, P. A. & Mueller, J. W. SULFATION PATHWAYS: insights into steroid sulfation and desulfation pathways. J. Mol. Endocrinol. 61, T271–T283 (2018).
pubmed: 29764919
Sun, N. et al. Prognostic relevance of steroid sulfation in adrenocortical carcinoma revealed by molecular phenotyping using high-resolution mass spectrometry imaging. Clin. Chem. 65, 1276–1286 (2019).
pubmed: 31492715
Sigala, S. et al. A comprehensive investigation of steroidogenic signaling in classical and new experimental cell models of adrenocortical carcinoma. Cells 11, 1439 (2022).
pubmed: 35563746
pmcid: 9103477
Fujisawa, Y. et al. Combined steroidogenic characters of fetal adrenal and Leydig cells in childhood adrenocortical carcinoma. J. Steroid Biochem. Mol. Biol. 159, 86–93 (2016).
pubmed: 26940356
Marti, N. et al. Androgen production in pediatric adrenocortical tumors may occur via both the classic and/or the alternative backdoor pathway. Mol. Cell Endocrinol. 452, 64–73 (2017).
pubmed: 28501574
Fenske, W. et al. Glucose transporter GLUT1 expression is an stage-independent predictor of clinical outcome in adrenocortical carcinoma. Endocr. Relat. Cancer 16, 919–928 (2009).
pubmed: 19465749
Satoh, K., Patel, D., Dieckmann, W., Nilubol, N. & Kebebew, E. Whole body metabolic tumor volume and total lesion glycolysis predict survival in patients with adrenocortical carcinoma. Ann. Surg. Oncol. 22 (Suppl. 3), S714–S720 (2015).
pubmed: 26282908
Wrenn, S. M. et al. Higher SUV
pubmed: 36137821
Pinheiro, C. et al. GLUT1 expression in pediatric adrenocortical tumors: a promising candidate to predict clinical behavior. Oncotarget 8, 63835–63845 (2017).
pubmed: 28969033
pmcid: 5609965
Assié, G. et al. Value of molecular classification for prognostic assessment of adrenocortical carcinoma. JAMA Oncol. 5, 1440–1447 (2019).
pubmed: 31294750
de Reyniès, A. et al. Gene expression profiling reveals a new classification of adrenocortical tumors and identifies molecular predictors of malignancy and survival. J. Clin. Oncol. 27, 1108–1115 (2009).
pubmed: 19139432
Marquardt, A. et al. Identifying new potential biomarkers in adrenocortical tumors based on mrna expression data using machine learning. Cancers 13, 4671 (2021).
pubmed: 34572898
pmcid: 8469239
Yi, X. et al. Identification of four novel prognostic biomarkers and construction of two nomograms in adrenocortical carcinoma: a multi-omics data study via bioinformatics and machine learning methods. Front. Mol. Biosci. 9, 878073 (2022).
pubmed: 35693556
pmcid: 9174903
Paré, L. et al. Association between PD1 mRNA and response to anti-PD1 monotherapy across multiple cancer types. Ann. Oncol. 29, 2121–2128 (2018).
pubmed: 30165419
Thorsson, V. et al. The immune landscape of cancer. Immunity 48, 812–830.e14 (2018).
pubmed: 29628290
pmcid: 5982584
Mohan, D. R., Lerario, A. M. & Hammer, G. D. Therapeutic targets for adrenocortical carcinoma in the genomics era. J. Endocr. Soc. 2, 1259–1274 (2018).
pubmed: 30402590
pmcid: 6215083
Tian, X. et al. Identification of tumor-infiltrating immune cells and prognostic validation of tumor-infiltrating mast cells in adrenocortical carcinoma: results from bioinformatics and real-world data. Oncoimmunology 9, 1784529 (2020).
pubmed: 32923148
pmcid: 7458645
Newman, A. M. et al. Robust enumeration of cell subsets from tissue expression profiles. Nat. Methods 12, 453–457 (2015).
pubmed: 25822800
pmcid: 4739640
Landwehr, L. S. et al. Interplay between glucocorticoids and tumor-infiltrating lymphocytes on the prognosis of adrenocortical carcinoma. J. Immunother. Cancer 8, e000469 (2020).
pubmed: 32474412
pmcid: 7264832
Coutinho, A. E. & Chapman, K. E. The anti-inflammatory and immunosuppressive effects of glucocorticoids, recent developments and mechanistic insights. Mol. Cell Endocrinol. 335, 2–13 (2011).
pubmed: 20398732
pmcid: 3047790
Marx, C., Wolkersdorfer, G. W., Brown, J. W., Scherbaum, W. A. & Bornstein, S. R. MHC class II expression—a new tool to assess dignity in adrenocortical tumours. J. Clin. Endocrinol. Metab. 81, 4488–4491 (1996).
pubmed: 8954065
Ozdemirli, M. et al. Fas (CD95)/Fas ligand interactions regulate antigen-specific, major histocompatibility complex-restricted T/B cell proliferative responses. Eur. J. Immunol. 26, 415–419 (1996).
pubmed: 8617312
Brunner, T. et al. Cell-autonomous Fas (CD95)/Fas-ligand interaction mediates activation-induced apoptosis in T-cell hybridomas. Nature 373, 441–444 (1995).
pubmed: 7530336
Wolkersdörfer, G. W. et al. Prevalence of HLA-DRB1 genotype and altered Fas/Fas ligand expression in adrenocortical carcinoma. J. Clin. Endocrinol. Metab. 90, 1768–1774 (2005).
pubmed: 15585555
Hahne, M. et al. Melanoma cell expression of Fas(Apo-1/CD95) ligand: implications for tumor immune escape. Science 274, 1363–1366 (1996).
pubmed: 8910274
Xiao, W. et al. Loss of fas expression and function is coupled with colon cancer resistance to immune checkpoint inhibitor immunotherapy. Mol. Cancer Res. 17, 420–430 (2019).
pubmed: 30429213
Pinto, E. M. et al. Prognostic significance of major histocompatibility complex class ii expression in pediatric adrenocortical tumors: a St. Jude and Children’s Oncology Group Study. Clin. Cancer Res. 22, 6247–6255 (2016).
pubmed: 27307598
pmcid: 5159323
Kanczkowski, W. et al. Abrogation of TLR4 and CD14 expression and signaling in human adrenocortical tumors. J. Clin. Endocrinol. Metab. 95, E421–E429 (2010).
pubmed: 20826579
Huang, B. et al. Toll-like receptors on tumor cells facilitate evasion of immune surveillance. Cancer Res. 65, 5009–5014 (2005).
pubmed: 15958541
Szajnik, M. et al. TLR4 signaling induced by lipopolysaccharide or paclitaxel regulates tumor survival and chemoresistance in ovarian cancer. Oncogene 28, 4353–4363 (2009).
pubmed: 19826413
pmcid: 2794996
Liang, J. et al. Clinicopathological and prognostic characteristics of CD276 (B7-H3) expression in adrenocortical carcinoma. Dis. Markers 2020, 5354825 (2020).
pubmed: 31998416
pmcid: 6977319
Hofmeyer, K. A., Ray, A. & Zang, X. The contrasting role of B7-H3. Proc. Natl Acad. Sci. USA 105, 10277–10278 (2008).
pubmed: 18650376
pmcid: 2492485
Liao, H., Ding, M., Zhou, N., Yang, Y. & Chen, L. B7-H3 promotes the epithelial-mesenchymal transition of NSCLC by targeting SIRT1 through the PI3K/AKT pathway. Mol. Med. Rep. 25, 79 (2022).
pubmed: 35029291
pmcid: 8778653
Raj, N. et al. PD-1 blockade in advanced adrenocortical carcinoma. J. Clin. Oncol. 38, 71–80 (2020).
pubmed: 31644329
Habra, M. A. et al. Phase II clinical trial of pembrolizumab efficacy and safety in advanced adrenocortical carcinoma. J. Immunother. Cancer 7, 253 (2019).
pubmed: 31533818
pmcid: 6751592
Head, L. et al. Response to immunotherapy in combination with mitotane in patients with metastatic adrenocortical cancer. J. Endocr. Soc. 3, 2295–2304 (2019).
pubmed: 31745526
pmcid: 6853671
Bedrose, S. et al. Combined lenvatinib and pembrolizumab as salvage therapy in advanced adrenal cortical carcinoma. J. Immunother. Cancer 8, e001009 (2020).
pubmed: 32737143
pmcid: 7394183
Carneiro, B. A. et al. Nivolumab in metastatic adrenocortical carcinoma: results of a phase 2 trial. J. Clin. Endocrinol. Metab. 104, 6193–6200 (2019).
pubmed: 31276163
McGregor, B. A. et al. Results of a multicenter, phase 2 study of nivolumab and ipilimumab for patients with advanced rare genitourinary malignancies. Cancer 127, 840–849 (2021).
pubmed: 33216356
Grondal, S., Eriksson, B., Hagenas, L., Werner, S. & Curstedt, T. Steroid profile in urine: a useful tool in the diagnosis and follow up of adrenocortical carcinoma. Acta Endocrinol. 122, 656–663 (1990).
US National Library of Medicine. ClinicalTrials.gov https://www.clinicaltrials.gov/study/NCT04373265 (2023).
US National Library of Medicine. ClinicalTrials.gov https://www.clinicaltrials.gov/study/NCT04187404 (2023).
Armignacco, R. et al. The adipose stem cell as a novel metabolic actor in adrenocortical carcinoma progression: evidence from an in vitro tumor microenvironment crosstalk model. Cancers 11, 1931 (2019).
pubmed: 31817072
pmcid: 6966501
Jain, M. et al. TOP2A is overexpressed and is a therapeutic target for adrenocortical carcinoma. Endocr. Relat. Cancer 20, 361–370 (2013).
pubmed: 23533247
pmcid: 4990817
Satoh, K. et al. Identification of niclosamide as a novel anticancer agent for adrenocortical carcinoma. Clin. Cancer Res. 22, 3458–3466 (2016).
pubmed: 26873959
pmcid: 4947455
Jain, M. et al. Interleukin-13 receptor alpha2 is a novel therapeutic target for human adrenocortical carcinoma. Cancer 118, 5698–5708 (2012).
pubmed: 22570059
Barton, D. E., Foellmer, B. E., Wood, W. I. & Francke, U. Chromosome mapping of the growth hormone receptor gene in man and mouse. Cytogenet. Cell Genet. 50, 137–141 (1989).
pubmed: 2776481
Hantel, C. et al. Targeting heterogeneity of adrenocortical carcinoma: evaluation and extension of preclinical tumor models to improve clinical translation. Oncotarget 7, 79292–79304 (2016).
pubmed: 27764813
pmcid: 5346714
Cardoso, C. C., Bornstein, S. R. & Hornsby, P. J. Optimizing orthotopic cell transplantation in the mouse adrenal gland. Cell Transpl. 19, 565–572 (2010).
Ruggiero, C., Doghman-Bouguerra, M. & Lalli, E. How good are the current models of adrenocortical carcinoma for novel drug discovery? Expert Opin. Drug Discov. 17, 211–213 (2022).
pubmed: 34666583
Batisse-Lignier, M. et al. p53/Rb inhibition induces metastatic adrenocortical carcinomas in a preclinical transgenic model. Oncogene 36, 4445–4456 (2017). This study demonstrates that known genetic alterations in human adrenocortical carcinoma introduced into a mouse can cause adrenocortical carcinoma similar in phenotype and histology to those human tumours and that this mouse model can in turn be used to evaluate the efficacy of targeted therapies.
pubmed: 28368424
Borges, K. S. et al. Wnt/β-catenin activation cooperates with loss of p53 to cause adrenocortical carcinoma in mice. Oncogene 39, 5282–5291 (2020).
pubmed: 32561853
pmcid: 7378041
Warde, K. M. et al. Senescence-induced immune remodeling facilitates metastatic adrenal cancer in a sex-dimorphic manner. Nat. Aging 3, 846–865 (2023).
pubmed: 37231196
Wilmouth, J. J. Jr. et al. Sexually dimorphic activation of innate antitumor immunity prevents adrenocortical carcinoma development. Sci. Adv. 8, eadd0422 (2022).
pubmed: 36240276
pmcid: 9565812
Lyraki, R. et al. Crosstalk between androgen receptor and WNT/β-catenin signaling causes sex-specific adrenocortical hyperplasia in mice. Dis. Model. Mech. 16, dmm050053 (2023).
pubmed: 37102205
pmcid: 10184674
Kiseljak-Vassiliades, K. et al. Development of new preclinical models to advance adrenocortical carcinoma research. Endocr. Relat. Cancer 25, 437–451 (2018).
pubmed: 29371329
pmcid: 5831504
Lang, J. et al. Development of an adrenocortical cancer humanized mouse model to characterize anti-pd1 effects on tumor microenvironment. J. Clin. Endocrinol. Metab. 105, 26–42 (2020). This study develops a humanized adrenocortical carcinoma PDX mouse model to assess immunotherapy responses.
pubmed: 31513709
Pinto, E. M. et al. Establishment and characterization of the first pediatric adrenocortical carcinoma xenograft model identifies topotecan as a potential chemotherapeutic agent. Clin. Cancer Res. 19, 1740–1747 (2013).
pubmed: 23406775
pmcid: 3618554
Fiorentini, C. et al. Palbociclib inhibits proliferation of human adrenocortical tumor cells. Endocrine 59, 213–217 (2018).
pubmed: 28265858
Liang, R. et al. Targeted gene expression profile reveals CDK4 as therapeutic target for selected patients with adrenocortical carcinoma. Front. Endocrinol. 11, 219 (2020).
Hadjadj, D. et al. A hypothesis-driven approach identifies CDK4 and CDK6 inhibitors as candidate drugs for treatments of adrenocortical carcinomas. Aging 9, 2695–2716 (2017).
pubmed: 29283884
pmcid: 5764399
Nilubol, N. et al. Synergistic combination of flavopiridol and carfilzomib targets commonly dysregulated pathways in adrenocortical carcinoma and has biomarkers of response. Oncotarget 9, 33030–33042 (2018).
pubmed: 30250647
pmcid: 6152480
Doghman, M. et al. Regulation of insulin-like growth factor-mammalian target of rapamycin signaling by microRNA in childhood adrenocortical tumors. Cancer Res. 70, 4666–4675 (2010).
pubmed: 20484036
pmcid: 2880211
Doghman, M., Cazareth, J. & Lalli, E. The T cell factor/beta-catenin antagonist PKF115-584 inhibits proliferation of adrenocortical carcinoma cells. J. Clin. Endocrinol. Metab. 93, 3222–3225 (2008).
pubmed: 18544621
Gaujoux, S. et al. Silencing mutated β-catenin inhibits cell proliferation and stimulates apoptosis in the adrenocortical cancer cell line H295R. PLoS ONE 8, e55743 (2013).
pubmed: 23409032
pmcid: 3567123
Cerquetti, L. et al. Rosiglitazone induces autophagy in H295R and cell cycle deregulation in SW13 adrenocortical cancer cells. Exp. Cell Res. 317, 1397–1410 (2011).
pubmed: 21376716
Cantini, G. et al. Rosiglitazone inhibits adrenocortical cancer cell proliferation by interfering with the IGF-IR intracellular signaling. PPAR Res. 2008, 904041 (2008).
pubmed: 18670617
pmcid: 2491299
Ferruzzi, P. et al. Thiazolidinediones inhibit growth and invasiveness of the human adrenocortical cancer cell line H295R. J. Clin. Endocrinol. Metab. 90, 1332–1339 (2005).
pubmed: 15585569
Sirianni, R. et al. Targeting estrogen receptor-α reduces adrenocortical cancer (ACC) cell growth in vitro and in vivo: potential therapeutic role of selective estrogen receptor modulators (SERMs) for ACC treatment. J. Clin. Endocrinol. Metab. 97, E2238–E2250 (2012).
pubmed: 23074235
Chimento, A. et al. GPER agonist G-1 decreases adrenocortical carcinoma (ACC) cell growth in vitro and in vivo. Oncotarget 6, 19190–19203 (2015).
pubmed: 26131713
pmcid: 4662484
Casaburi, I. et al. Estrogen related receptor α (ERRα) a promising target for the therapy of adrenocortical carcinoma (ACC). Oncotarget 6, 25135–25148 (2015).
pubmed: 26312764
pmcid: 4694820
Tamburello, M. et al. Preclinical evidence of progesterone as a new pharmacological strategy in human adrenocortical carcinoma cell lines. Int. J. Mol. Sci. 24, 6829 (2023).
pubmed: 37047801
pmcid: 10095539
Doghman, M. et al. Inhibition of adrenocortical carcinoma cell proliferation by steroidogenic factor-1 inverse agonists. J. Clin. Endocrinol. Metab. 94, 2178–2183 (2009).
pubmed: 19318454
pmcid: 2690427
Cheng, Y., Kerppola, R. E. & Kerppola, T. K. ATR-101 disrupts mitochondrial functions in adrenocortical carcinoma cells and in vivo. Endocr. Relat. Cancer 23, 1–19 (2016).
pubmed: 26843528
pmcid: 4887102
LaPensee, C. R. et al. ATR-101, a selective and potent inhibitor of acyl-CoA acyltransferase 1, induces apoptosis in h295r adrenocortical cells and in the adrenal cortex of dogs. Endocrinology 157, 1775–1788 (2016).
pubmed: 26986192
Subramanian, C. et al. Synthetic high-density lipoprotein nanoparticles: a novel therapeutic strategy for adrenocortical carcinomas. Surgery 159, 284–294 (2016).
pubmed: 26582501
Bussey, K. J. et al. Targeting polo-like kinase 1, a regulator of p53, in the treatment of adrenocortical carcinoma. Clin. Transl. Med. 5, 1 (2016).
pubmed: 26754547
pmcid: 4709336
Martarelli, D., Pompei, P., Baldi, C. & Mazzoni, G. Mebendazole inhibits growth of human adrenocortical carcinoma cell lines implanted in nude mice. Cancer Chemother. Pharmacol. 61, 809–817 (2008).
pubmed: 17581752
Poli, G. et al. Metformin as a new anti-cancer drug in adrenocortical carcinoma. Oncotarget 7, 49636–49648 (2016).
pubmed: 27391065
pmcid: 5226535
Glover, A. R. et al. MicroRNA-7 as a tumor suppressor and novel therapeutic for adrenocortical carcinoma. Oncotarget 6, 36675–36688 (2015).
pubmed: 26452132
pmcid: 4742203
Babińska, A., Pęksa, R., Wiśniewski, P., Świątkowska-Stodulska, R. & Sworczak, K. Diagnostic and prognostic role of SF1, IGF2, Ki67, p53, adiponectin, and leptin receptors in human adrenal cortical tumors. J. Surg. Oncol. 116, 427–433 (2017).
pubmed: 28672049
Liu, S., Ding, G., Zhou, Z. & Feng, C. β-Catenin-driven adrenocortical carcinoma is characterized with immune exclusion. Onco Targets Ther. 11, 2029–2036 (2018).
pubmed: 29670378
pmcid: 5898592
Pennanen, M. et al. C-myc expression in adrenocortical tumours. J. Clin. Pathol. 71, 129–134 (2018).
pubmed: 28801349
Fernandez-Ranvier, G. G. et al. Identification of biomarkers of adrenocortical carcinoma using genomewide gene expression profiling. Arch. Surg. 143, 841–846 (2008).
pubmed: 18794420
Aporowicz, M. et al. Minichromosome maintenance proteins MCM-3, MCM-5, MCM-7, and Ki-67 as proliferative markers in adrenocortical tumors. Anticancer Res. 39, 1151–1159 (2019).
pubmed: 30842144
Cheng, Y., Kou, W., Zhu, D., Yu, X. & Zhu, Y. Future directions in diagnosis, prognosis and disease monitoring of adrenocortical carcinoma: novel non-invasive biomarkers. Front. Endocrinol. 12, 811293 (2021).
Mytareli, C. et al. The diagnostic, prognostic and therapeutic role of mirnas in adrenocortical carcinoma: a systematic review. Biomedicines 9, 1501 (2021).
pubmed: 34829730
pmcid: 8614733
Cantini, G. et al. Prognostic and monitoring value of circulating tumor cells in adrenocortical carcinoma: a preliminary monocentric study. Cancers 12, 3176 (2020).
pubmed: 33138000
pmcid: 7693770
Creemers, S. G. et al. Identification of mutations in cell-free circulating tumor DNA in adrenocortical carcinoma: a case series. J. Clin. Endocrinol. Metab. 102, 3611–3615 (2017).
pubmed: 28973495
Zhang, F. et al. Prognostic role of Ki-67 in adrenocortical carcinoma after primary resection: a retrospective mono-institutional study. Adv. Ther. 36, 2756–2768 (2019).
pubmed: 31471770
Xu, W. H. et al. Screening and identification of potential prognostic biomarkers in adrenocortical carcinoma. Front. Genet. 10, 821 (2019).
pubmed: 31572440
pmcid: 6749084
Fragoso, M. C. et al. Combined expression of BUB1B, DLGAP5, and PINK1 as predictors of poor outcome in adrenocortical tumors: validation in a Brazilian cohort of adult and pediatric patients. Eur. J. Endocrinol. 166, 61–67 (2012).
pubmed: 22048964
Sbiera, S. et al. Assessment of VAV2 expression refines prognostic prediction in adrenocortical carcinoma. J. Clin. Endocrinol. Metab. 102, 3491–3498 (2017).
pubmed: 28911143
Faria, A. M. & Almeida, M. Q. Differences in the molecular mechanisms of adrenocortical tumorigenesis between children and adults. Mol. Cell Endocrinol. 351, 52–57 (2012).
pubmed: 22019901
Sbiera, S. et al. High diagnostic and prognostic value of steroidogenic factor-1 expression in adrenal tumors. J. Clin. Endocrinol. Metab. 95, E161–E171 (2010).
pubmed: 20660055
Miller, B. S., Gauger, P. G., Hammer, G. D., Giordano, T. J. & Doherty, G. M. Proposal for modification of the ENSAT staging system for adrenocortical carcinoma using tumor grade. Langenbecks Arch. Surg. 395, 955–961 (2010).
pubmed: 20694732
Mermejo, L. M. et al. Altered expression of noncanonical Wnt pathway genes in paediatric and adult adrenocortical tumours. Clin. Endocrinol. 81, 503–510 (2014).
Lavoie, J. M. et al. Whole-genome and transcriptome analysis of advanced adrenocortical cancer highlights multiple alterations affecting epigenome and DNA repair pathways. Cold Spring Harb. Mol. Case Stud. 8, a006148 (2022).
pubmed: 35483882
pmcid: 9059790
Legendre, C. R. et al. pathway implications of aberrant global methylation in adrenocortical cancer. PLoS ONE 11, e0150629 (2016).
pubmed: 26963385
pmcid: 4786116
Fonseca, A. L. et al. Comprehensive DNA methylation analysis of benign and malignant adrenocortical tumors. Genes Chromosomes Cancer 51, 949–960 (2012).
pubmed: 22733721
Gao, Z. H. et al. Association of H19 promoter methylation with the expression of H19 and IGF-II genes in adrenocortical tumors. J. Clin. Endocrinol. Metab. 87, 1170–1176 (2002).
pubmed: 11889182
Arlt, W. et al. Urine steroid metabolomics as a biomarker tool for detecting malignancy in adrenal tumors. J. Clin. Endocrinol. Metab. 96, 3775–3784 (2011).
pubmed: 21917861
pmcid: 3232629